2025
Changes in glucose level during chemotherapy treatment in patients with stage I–IV breast cancer
Schnell P, Kassem M, Miah A, Ramaswamy B, Williams N, Cherian M, Stover D, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, Sudheendra P, Ormiston K, Mezzanotte J, Orchard T, Lustberg M. Changes in glucose level during chemotherapy treatment in patients with stage I–IV breast cancer. Clinical Breast Cancer 2025 PMID: 40541466, DOI: 10.1016/j.clbc.2025.05.021.Peer-Reviewed Original ResearchStage I-IV breast cancerBreast cancerGlucose dysregulationGlucose levelsBlood glucoseChemotherapy treatment of patientsChemotherapy treatmentNCI-designated Comprehensive Cancer CenterTreatment of patientsComprehensive cancer centerBaseline glucose levelsRandom blood glucoseRandom glucose levelsChemotherapy regimenBlood glucose levelsChemotherapyStatistically significant changesHistopathological dataDiabetes mellitusWorsening morbidityCancer CenterBaseline variablesPatientsStudy populationAppropriate management
2024
Learning what keeps nanomedicines in tumours
Wang Y, Schrank B, Jiang W, Kim B. Learning what keeps nanomedicines in tumours. Nature Biomedical Engineering 2024, 8: 1330-1331. PMID: 39271934, DOI: 10.1038/s41551-024-01251-1.Peer-Reviewed Original Research
2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilance
2012
Diagnostic utility and correlation of tumor markers in the serum and cerebrospinal fluid of children with intracranial germ cell tumors
Qaddoumi I, Sane M, Li S, Kocak M, Pai-Panandiker A, Harreld J, Klimo P, Wright K, Broniscer A, Gajjar A. Diagnostic utility and correlation of tumor markers in the serum and cerebrospinal fluid of children with intracranial germ cell tumors. Child's Nervous System 2012, 28: 1017-1024. PMID: 22547227, PMCID: PMC3526807, DOI: 10.1007/s00381-012-1762-4.Peer-Reviewed Original ResearchConceptsGerm cell tumorsIntracranial germ cell tumorsFollow-up examinationAlpha-fetoproteinCerebrospinal fluidCell tumorsTumor markersDiagnosis of germ cell tumorsCerebrospinal fluid alpha-fetoproteinDiagnostic utilityBeta-human chorionic gonadotropinRetrospective study of patientsCerebrospinal fluid of childrenSerum AFP valuesAlpha-fetoprotein valuesStudy of patientsHuman chorionic gonadotropinTumor relapseAFP valuesArea under curveHistopathological diagnosisRetrospective studyChorionic gonadotropinLogistic regression modelsHistopathological data
2007
Carcinoid of the Rectum Risk Stratification (CaRRs): A Strategy for Preoperative Outcome Assessment
Fahy B, Tang L, Klimstra D, Wong W, Guillem J, Paty P, Temple L, Shia J, Weiser M. Carcinoid of the Rectum Risk Stratification (CaRRs): A Strategy for Preoperative Outcome Assessment. Annals Of Surgical Oncology 2007, 14: 1735-1743. PMID: 17294074, DOI: 10.1245/s10434-006-9311-6.Peer-Reviewed Original ResearchConceptsElevated mitotic rateLymphovascular invasionTumor sizeMitotic rateRisk stratificationDeep invasionPresence of lymphovascular invasionAssociated with larger tumor sizePre-operative biopsyDisease-specific survivalFactors associated with outcomesLarger tumor sizeRisk stratification schemesResultsThe mean ageRecurrence-freeCarcinoid patientsDistant metastasisInvasive tumorsPrognostic featuresPoor prognosisRectal carcinoidsHistopathological dataPoor outcomeMean ageTumor
2006
Carcinoid of the Rectum Risk Stratification (CaRRS): A Strategy for Preoperative Outcome Assessment
Fahy B, Tang L, Klimstra D, Wong W, Guillem J, Paty P, Temple L, Shia J, Weiser M. Carcinoid of the Rectum Risk Stratification (CaRRS): A Strategy for Preoperative Outcome Assessment. Annals Of Surgical Oncology 2006, 14: 396-404. PMID: 17094024, DOI: 10.1245/s10434-006-9197-3.Peer-Reviewed Original ResearchConceptsIncreased mitotic rateLymphovascular invasionTumor sizeMitotic rateRisk stratificationRectal carcinoidsDeep invasionPresence of lymphovascular invasionAssociated with larger tumor sizeDied of diseaseDisease-specific survivalFactors associated with outcomesLarger tumor sizeRisk stratification schemesResultsThe mean agePreoperative biopsyRecurrence-freeDistant metastasisPrognostic featuresFavorable prognosisInvasive tumorsMethodsSeventy patientsPoor prognosisPoor outcomeHistopathological data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply